ADMA Biologics Inc — Cash Flow (NASDAQ:ADMA) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities -102 M-112.37 M-59.51 M8.8 M118.67 M50.4 M 50.4 M Cash from investing activities -12.72 M-13.51 M-13.91 M4.98 M8.57 M21.89 M 21.89 M Cash from financing activities 143.9 M121.05 M108.85 M38.99 M58.3 M44.02 M 44.02 M Free cash flow -114.73 M-125.88 M-73.42 M3.82 M110.1 M27.5 M 27.5 M

Nachrichten

Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change

ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance

Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues

ADMA Biologics Inc: EPS übertrifft Schätzungen um 0,03 $ - Umsatz schlechter als erwartet

ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates

ADMA Biologics vor Quartalszahlen: Bewährungsprobe für ambitionierte Wachstumsziele

Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?

ADMA Biologics: CEO Adam Grossman verkauft Aktien im Wert von 337.679 US-Dollar

Adam Grossman, president of Adma Biologics, sells $337,679 in shares

Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer

NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro

Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note